No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IMMX240517C10000
- 0.00
- 0.000.00%
15min DelayTrading May 15 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.00%IV522.41%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma0.48Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
No Data
News
Immix Biopharma(IMMX.US) Officer Buys US$9,659.95 in Common Stock
$Immix Biopharma(IMMX.US)$ Officer Rachman Ilya M purchased 4,300 shares of common stock on May 14, 2024 at an average price of $2.2465 for a total value of $9,659.95.Source: Announcement What is stat
Immix Biopharma(IMMX.US) Officer Buys US$10,041.75 in Common Stock
$Immix Biopharma(IMMX.US)$ Officer Morris Gabriel S purchased 4,500 shares of common stock on May 14, 2024 at an average price of $2.2315 for a total value of $10,041.75.Source: Announcement What is s
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of
Immix Biopharma | 10-Q: Quarterly report
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment
Immix Biopharma (IMMX) said Monday that the European Commission has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma. The designation qualifies NXC-201 among others for
Express News | Immix Biopharma Awarded European Union Orphan Drug Designation for Nxc-201 in Multiple Myeloma
Comments
$Immix Biopharma(IMMX.US$
NEWS
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma, Inc. has been granted European Orphan Drug Designation for NXC-201 in the treatment of multiple myeloma, providing 10 years of market exclusivity, access to centralized authorization procedure, and reduced fees for various applications. The Company aims to address unmet medical needs in frail patients with relapsed/refractory multiple myeloma, with poten...
NEWS
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma, Inc. has been granted European Orphan Drug Designation for NXC-201 in the treatment of multiple myeloma, providing 10 years of market exclusivity, access to centralized authorization procedure, and reduced fees for various applications. The Company aims to address unmet medical needs in frail patients with relapsed/refractory multiple myeloma, with poten...
3
$Immix Biopharma(IMMX.US$ Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
MT Newswires· 1 min ago
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation visits at US testing locations this month and May.
The open-label, phase 1b dose-expansion trial is expected to enroll around 40 patients with adequate cardia...
MT Newswires· 1 min ago
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation visits at US testing locations this month and May.
The open-label, phase 1b dose-expansion trial is expected to enroll around 40 patients with adequate cardia...
$Immix Biopharma(IMMX.US$
NEWS
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated...
NEWS
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated...
$Immix Biopharma(IMMX.US$ Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
$Immix Biopharma(IMMX.US$ Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
5 MINUTES AGO, 4:45 PM EST
VIA GLOBENEWSWIRE![]()
5 MINUTES AGO, 4:45 PM EST
VIA GLOBENEWSWIRE
Read more